Liat Izhak

发表

Balance is a key for happiness

J. Berzofsky, M. Terabe, Liat Izhak, 2013, Oncoimmunology.

Delicate balance among three types of T cells in concurrent regulation of tumor immunity.

J. Berzofsky, D. Venzon, S. Kato, 2013, Cancer research.

DelicateBalanceamongThreeTypesofTCellsinConcurrent Regulation of Tumor Immunity

J. Berzofsky, D. Venzon, S. Kato, 2013 .

A Novel Recombinant Fusion Protein Encoding a 20-Amino Acid Residue of the Third Extracellular (E3) Domain of CCR2 Neutralizes the Biological Activity of CCL21

E. Yefenof, R. Anunu, J. Seagal, 2009, The Journal of Immunology.

Neutralizes the Biological Activity of CCL2 Third Extracellular (E3) Domain of CCR2 Encoding a 20-Amino Acid Residue of the A Novel Recombinant Fusion Protein

E. Yefenof, R. Anunu, J. Seagal, 2009 .

Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity.

J. Berzofsky, G. Besra, Hee-Yong Kim, 2011, The Journal of clinical investigation.

Correction: Predominant Expression of CCL2 at the Tumor Site of Prostate Cancer Patients Directs a Selective Loss of Immunological Tolerance to CCL2 That Could Be Amplified in a Beneficial Manner

U. Weinberg, Y. Shaked, D. Dumont, 2018, The Journal of Immunology.

Abstract 3636: Potent antitumor activity of duvortuxizumab, a CD19 x CD3 DART® molecule, in lymphoma models

Syd Johnson, Dana E. Cullen, L. Luistro, 2017 .

Dissecting the Autocrine and Paracrine Roles of the CCR2-CCL2 Axis in Tumor Survival and Angiogenesis

Steffen Jung, Y. Shaked, N. Karin, 2012, PloS one.

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells

G. V. D. van der Windt, A. Kater, E. Eldering, 2020, Journal for immunotherapy of cancer.

Self-reactive IgE exacerbates interferon responses associated with autoimmunity

Michael A. Smith, D. Khatry, M. Petri, 2015, Nature Immunology.

Predominant Expression of CCL2 at the Tumor Site of Prostate Cancer Patients Directs a Selective Loss of Immunological Tolerance to CCL2 That Could Be Amplified in a Beneficial Manner

Y. Shaked, D. Dumont, J. Alami, 2009, The Journal of Immunology.

β-Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-Term Functional Anergy

J. Berzofsky, G. Besra, S. Kato, 2013, Clinical Cancer Research.

Predominant Expression of CCL2 at the Tumor Site of Prostate Cancer Patients Directs a Selective Loss of Immunological Tolerance to CCL2 That Could Be Amplified in a Beneficial Manner

Y. Shaked, D. Dumont, J. Alami, 2009, The Journal of Immunology.

The seventh author's name was omitted from the article. In addition, the third author's name was published incorrectly. The corrected author and affiliation lines are shown below.

U. Weinberg, Y. Shaked, D. Dumont, 2010 .

Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner

Y. Shaked, D. Dumont, J. Alami, 2010, The Journal of Immunology.

Abstract 460: Delicate balance among three types of T cells in concurrent regulation of tumor immunity.

J. Berzofsky, D. Venzon, S. Kato, 2013 .